Open Label, Observational Study for Children & Adolescent With Severe Asthma With an Eosinophilic Phenotype Treated With Mepolizumab
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms CASAM
- 05 Mar 2024 Planned End Date changed from 1 Dec 2024 to 12 Mar 2026.
- 05 Mar 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Mar 2026.
- 05 Mar 2024 Status changed from recruiting to active, no longer recruiting.